NO20015016L - Nye polymorfe former av et antidiabetisk middel; fremgangsmåte for deres fremstilling og farmasöytiskesammensetninger som inneholder dem - Google Patents

Nye polymorfe former av et antidiabetisk middel; fremgangsmåte for deres fremstilling og farmasöytiskesammensetninger som inneholder dem

Info

Publication number
NO20015016L
NO20015016L NO20015016A NO20015016A NO20015016L NO 20015016 L NO20015016 L NO 20015016L NO 20015016 A NO20015016 A NO 20015016A NO 20015016 A NO20015016 A NO 20015016A NO 20015016 L NO20015016 L NO 20015016L
Authority
NO
Norway
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
polymorphic forms
antidiabetic agent
Prior art date
Application number
NO20015016A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015016D0 (no
Inventor
Om Reddy Gaddam
Rajendra Kumar Potlapally
Raju Sirisilla
Vyas Krishnamurthi
Sreenivasa Rao Dharmaraja
Ramabhadra Sarma Mamillapalli
Original Assignee
Reddy Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en
Application filed by Reddy Research Foundation filed Critical Reddy Research Foundation
Publication of NO20015016D0 publication Critical patent/NO20015016D0/no
Publication of NO20015016L publication Critical patent/NO20015016L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20015016A 1999-04-16 2001-10-15 Nye polymorfe former av et antidiabetisk middel; fremgangsmåte for deres fremstilling og farmasöytiskesammensetninger som inneholder dem NO20015016L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (en) 1999-04-16 1999-04-16 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
IN436MA1999 1999-04-19
PCT/IB2000/000470 WO2000063192A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
NO20015016D0 NO20015016D0 (no) 2001-10-15
NO20015016L true NO20015016L (no) 2001-12-11

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015016A NO20015016L (no) 1999-04-16 2001-10-15 Nye polymorfe former av et antidiabetisk middel; fremgangsmåte for deres fremstilling og farmasöytiskesammensetninger som inneholder dem

Country Status (17)

Country Link
EP (1) EP1171430A1 (bg)
CN (1) CN1351597A (bg)
AU (1) AU3831300A (bg)
BG (1) BG106022A (bg)
BR (1) BR0010683A (bg)
CA (1) CA2370401A1 (bg)
CZ (1) CZ20013711A3 (bg)
EE (1) EE200100529A (bg)
HR (1) HRP20010748A2 (bg)
HU (1) HUP0200758A3 (bg)
IL (1) IL145958A0 (bg)
MX (1) MXPA01010472A (bg)
NO (1) NO20015016L (bg)
PL (1) PL351492A1 (bg)
RU (1) RU2001130883A (bg)
TR (1) TR200103851T2 (bg)
WO (1) WO2000063192A1 (bg)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634605A3 (en) 2000-03-08 2006-10-11 Novo Nordisk A/S treatment of dyslipidemia in a patient having type 2 diabetes
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
AU2002351748B2 (en) 2001-12-21 2009-07-09 Novo Nordisk A/S Amide derivatives as GK activators
CN1290843C (zh) * 2002-04-19 2006-12-20 费斯制药股份有限公司 4－[2－[4－[1－(2－乙氧基乙基)－1H－苯并咪唑－2－基]－1－哌啶基]乙基]－α,α－二甲基苯乙酸的多晶型物
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
JP2007503453A (ja) 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ 肥満症を治療するための新規化合物
EP1670815A2 (en) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
US7863329B2 (en) 2005-11-17 2011-01-04 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
EA016026B1 (ru) 2006-05-29 2012-01-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи 3-(1,3-бензодиоксол-5-ил)-6-(4-циклопропилпиперазин-1-ил)пиридазин, его соли и сольваты и его применение в качестве антагониста н3 рецептора гистамина
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
CA2792663A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
US20140031278A1 (en) 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
IN2014CN02448A (bg) 2011-09-23 2015-06-19 Novo Nordisk As
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
MA49883A (fr) 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (bg) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (fr) * 1996-03-13 1998-04-30 Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
JP2000511875A (ja) * 1996-06-19 2000-09-12 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病活性を増強されたトログリタゾンの新規な多形型及びそれらの製造方法
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU1887999A (en) * 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NZ504106A (en) * 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU3831300A (en) 2000-11-02
MXPA01010472A (es) 2002-05-06
EP1171430A1 (en) 2002-01-16
EE200100529A (et) 2002-12-16
TR200103851T2 (tr) 2002-04-22
IL145958A0 (en) 2002-07-25
RU2001130883A (ru) 2004-03-20
HUP0200758A2 (hu) 2002-07-29
NO20015016D0 (no) 2001-10-15
CN1351597A (zh) 2002-05-29
PL351492A1 (en) 2003-04-22
HUP0200758A3 (en) 2003-07-28
HRP20010748A2 (en) 2003-02-28
BG106022A (bg) 2002-04-30
WO2000063192A1 (en) 2000-10-26
BR0010683A (pt) 2003-07-01
CZ20013711A3 (cs) 2002-07-17
CA2370401A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
NO20015016L (no) Nye polymorfe former av et antidiabetisk middel; fremgangsmåte for deres fremstilling og farmasöytiskesammensetninger som inneholder dem
NO20003764D0 (no) Nye <beta>-karbolinforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
NO20011478L (no) Nye N-(iminometyl)aminderivater, fremgangsmåte for fremstilling derav, anvendelse som medikamenter og sammensetningerinneholdende dem
NO20014102L (no) Nye tricykliske forbindelser og deres anvendelse innenfor medisin, fremgangsmåte for deres fremstilling og farmasöytisksammensetning som inneholder dem
NO996250L (no) Nye hydrazidforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
NO971862D0 (no) Nye inhibitorer av metalloprotease, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20042805L (no) Nye forbindelser og deres anvendelse innen medisin, fremgangsmate for deres fremstilling og farmaoytiske sammensetninger som inneholder dem
NO20010522L (no) Nye piperidin-4-sulfonamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
NO20026154L (no) Nye substituerte ftalider, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20013206D0 (no) Nye 1,1- og 1,2-disubstituerte cyklopropanforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiskesammensetninger inneholdende dem
NO20015058D0 (no) Nye ribose-substituerte aromatiske amider, metode for fremstilling, og andvendelse derav som medikamenter
EE200300553A (et) Piperidiinkarboksamiidi derivaadid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid
NO20031643L (no) Nye aminotriazolonforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20034614L (no) Nye [3,4-a:3,4-c]karbazolforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DK1150970T3 (da) (1-phenacy-3-phenyl-3-piperidylethyl)piperidin-derivater, fremgangsmåde til deres fremstilling og farmaceutiske sammensætningner indeholdende dem
NO20021330D0 (no) Nye indenoindolonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
EE200100499A (et) Uued morfoliini derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
NO961677D0 (no) Nye cykloheksanforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20013710L (no) Nye benzotiadiazinforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20016069L (no) Nye bicykliske amino-pyrazinonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
NO20011862L (no) Nye heterocykloalkylbenzocyklobutan- og heteroarylbenzocyklobutanforbindelser, fremgangsmåte ved deresfremstilling og farmasöytiske sammensetninger inneholdende dem
NO20025393D0 (no) Optis 2-aminotetralinderivater, fremgangsmÕte ved fremstilling derav og terapeutisk anvendelse av farmasöytiskanvendelse av farmasöytiske sammensetninger inneholdende dem
NO20042447L (no) Nye benzo(a)pyranol[3,2-h]akridin-7-onforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20020262L (no) Nye cykloheptenforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20043532L (no) Nye 3-aryl-2,5-dihydroksy-1,4-benzokinonforbindelser, fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application